News
Public · Published
Buy Max Healthcare Institute; target of Rs 1080: Prabhudas Lilladher
Prabhudas Lilladher maintained a Buy rating on Max Healthcare Institute and set a target price of Rs 1080 per share. The report said quarterly EBITDA, a measure of operating earnings before interest, tax, depreciation and amortisation, rose 18% year over year to INR 8.2bn.
Published:
Updated:
What happened
Prabhudas Lilladher maintained a Buy rating on Max Healthcare Institute and set a target price of Rs 1080 per share. The report said quarterly EBITDA, a measure of operating earnings before interest, tax, depreciation and amortisation, rose 18% year over year to INR 8.2bn.
Confirmed
Global impact / market context
The report links future earnings growth to new beds, revised CGHS prices, and expanding or improving hospital units. If these changes bring more patients and revenue without a matching rise in costs, operating earnings could grow; delays or weaker demand would limit that benefit.
Analyst inference
The broker’s unchanged profit estimates and expected growth could support higher future earnings if new beds, pricing changes and unit improvements deliver. Its valuation uses forecast future operating earnings, so investors’ returns depend on those gains materialising and the shares’ valuation remaining supported.
Analyst inference
What to watch
- Check whether new beds at Nanavati, Mohali, and Max Smart open and fill as expected, since added capacity can raise revenue but also brings operating costs. Analyst inference
- Watch for the CGHS price revision to benefit revenue and for operations at Noida, Dwarka, and Kalinga to ramp up or improve, as the report expects. Analyst inference
- Track the effect of discontinued chemotherapy drugs for institutional patients, which the report says affected year-over-year growth and will enter the comparison base from Q3FY27. Confirmed
Evidence
- Original source link unavailable